docetaxel + pembrolizumab

Docetaxel + pembrolizumab is a combination therapy consisting of docetaxel, a cytotoxic taxane chemotherapy agent, and pembrolizumab, an immune checkpoint inhibitor targeting programmed cell death protein 1 (PD-1). Docetaxel disrupts microtubule function, inhibiting cell division and inducing apoptosis in cancer cells. Pembrolizumab is a monoclonal antibody that blocks PD-1 on T cells, enhancing the immune system's ability to recognize and destroy tumor cells. This combination has been investigated primarily for advanced or metastatic cancers such as non-small cell lung cancer (NSCLC) and metastatic castration-resistant prostate cancer (mCRPC), aiming to improve response rates by combining direct cytotoxic effects with immunotherapy-mediated anti-tumor activity[3][6].

Brand names

KeytrudaTaxotere

Other names

anti-PD-1 + docetaxelPD-1 inhibitor + docetaxelpembrolizumab plus docetaxelcamrelizumab + docetaxel